Distinguishing hepatic metastasis from hemangioma using gadoxetic acid-enhanced magnetic resonance imaging

Investigative Radiology

Volumn 46, Issue 6, 2011, Pages 359-365

  Motosugi, Utaroh ^a   Ichikawa, Tomoaki ^a   Onohara, Kojiro ^a   Sou, Hironobu ^a   Sano, Katsuhiro ^a   Muhi, Ali ^a   Araki, Tsutomu ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

gadoxetic acid; hemangioma; Liver; magnetic resonance imaging; metastasis

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HEMANGIOMA; HUMAN; IMAGE ANALYSIS; LIVER CELL; LIVER METASTASIS; MALE; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 79955876504     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3182104b77     Document Type: Article

References (38)

1. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010; 45:133-141.
2. Kogita S, Imai Y, Okada M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol. 2010;20:2405-2413.
3. Kim YK, Kim CS, Han YM, et al. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging? Invest Radiol. 2010;45:740-746.
4. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas
5. Kim SH, Lee J, Kim MJ, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. Am J Roentgenol. 2009;192:1675-1681.
6. Araki T, Itai Y, Furui S, et al. Dynamic CT densitometry of hepatic tumors. Am J Roentgenol. 1980;135:1037-1043. (Pubitemid 11236978)
7. Itai Y, Furui S, Araki T, et al. Computed tomography of cavernous hemangioma of the liver. Radiology. 1980;137:149-155. (Pubitemid 10002564)
8. Caseiro-Alves F, Brito J, Araujo AE, et al. Liver haemangioma: common and uncommon findings and how to improve the differential diagnosis. Eur Radiol. 2007;17:1544-1554. (Pubitemid 46767603)
9. Ba-Ssalamah A, Uffmann M, Saini S, et al. Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol. 2009;19:342-357.
10. Doo KW, Lee CH, Choi JW, et al. "Pseudo washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. Am J Roentgenol. 2009;193:W490-W496.
11. Kim T, Federle MP, Baron RL, et al. Discrimination of small hepatic hemangiomas from hypervascular malignant tumors smaller than 3 cm with three-phase helical CT. Radiology. 2001;219:699-706. (Pubitemid 32476260)
12. Jang HJ, Kim TK, Lim HK, et al. Hepatic hemangioma: atypical appearances on CT, MR imaging, and sonography. Am J Roentgenol. 2003;180:135-141. (Pubitemid 36008700)
13. Jang HJ, Choi BI, Kim TK, et al. Atypical small hemangiomas of the liver: "bright dot" sign at two-phase spiral CT. Radiology. 1998;208:543-548. (Pubitemid 28373769)
14. Nino-Murcia M, Olcott EW, Jeffrey RB Jr, et al. Focal liver lesions: pattern-based classification scheme for enhancement at arterial phase CT. Radiology. 2000;215:746-751. (Pubitemid 30346009)
15. Yu JS, Kim KW, Park MS, et al. Transient peritumoral enhancement during dynamic MRI of the liver: cavernous hemangioma versus hepatocellular carcinoma. J Comput Assist Tomogr. 2002;26:411-417. (Pubitemid 34564220)
16. Li CS, Chen RC, Chen WT, et al. Temporal peritumoral enhancement of hepatic cavernous hemangioma: findings at multiphase dynamic magnetic resonance imaging. J Comput Assist Tomogr. 2003;27:854-859.
17. Jeong MG, Yu JS, Kim KW. Hepatic cavernous hemangioma: temporal peritu-moral enhancement during multiphase dynamic MR imaging. Radiology. 2000; 216:692-697.
18. Kim KW, Kim TK, Han JK, et al. Hepatic hemangiomas with arterioportal shunt: findings at two-phase CT. Radiology. 2001;219:707-711. (Pubitemid 32476261)
19. Mastropasqua M, Kanematsu M, Leonardou P, et al. Cavernous hemangiomas in patients with chronic liver disease: MR imaging findings. Magn Reson Imaging. 2004;22:15-18. (Pubitemid 38221578)
20. Berger JF, Laissy JP, Limot O, et al. Differentiation between multiple liver hemangiomas and liver metastases of gastrinomas: value of enhanced MRI. J Comput Assist Tomogr. 1996;20:349-355. (Pubitemid 26142282)
21. Kim YH, Saini S, Blake MA, et al. Distinguishing hepatic metastases from hemangiomas: qualitative and quantitative diagnostic performance through dual echo respiratory-triggered fast spin echo magnetic resonance imaging. J Comput Assist Tomogr. 2005;29:571-579. (Pubitemid 41395765)
22. Soyer P, Dufresne AC, Somveille E, et al. Hepatic cavernous hemangioma: appearance on T2-weighted fast spin-echo MR imaging with and without fat suppression. Am J Roentgenol. 1997;168:461-465. (Pubitemid 27051989)
23. Semelka RC, Brown ED, Ascher SM, et al. Hepatic hemangiomas: a multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images. Radiology. 1994;192:401-406.
24. Marti-Bonmati L, Casillas C, Graells M, et al. Atypical hepatic hemangiomas with intense arterial enhancement and early fading. Abdom Imaging. 1999; 24:147-152. (Pubitemid 29117597)
25. Kato H, Kanematsu M, Matsuo M, et al. Atypically enhancing hepatic cavernous hemangiomas: high-spatial-resolution gadolinium-enhanced triphasic dynamic gradient-recalled-echo imaging findings. Eur Radiol. 2001;11:2510-2515. (Pubitemid 33114908)
26. Danet IM, Semelka RC, Braga L, et al. Giant hemangioma of the liver: MR imaging characteristics in 24 patients. Magn Reson Imaging. 2003;21:95-101. (Pubitemid 36418727)
27. Mitchell DG, Saini S, Weinreb J, et al. Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-en-hanced MR imaging. Radiology. 1994;193:49-57. (Pubitemid 24297998)
28. Bennett GL, Petersein A, Mayo-Smith WW, et al. Addition of gadolinium chelates to heavily T2-weighted MR imaging: limited role in differentiating hepatic hemangiomas from metastases. Am J Roentgenol. 2000;174:477-485. (Pubitemid 30067162)
29. Outwater EK, Ito K, Siegelman E, et al. Rapidly enhancing hepatic heman-giomas at MRI: distinction from malignancies with T2-weighted images. J Magn Reson Imaging. 1997;7:1033-1039. (Pubitemid 28372878)
30. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology. 2005;234:468-478. (Pubitemid 40139918)
31. Reimer P, Rummeny EJ, Daldrup HE, et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol. 1997;7: 275-280. (Pubitemid 127538595)
32. Nakamura Y, Ohmoto T, Saito T, et al. Effects of gadolinium-ethoxybenzyl- diethylenetriamine pentaacetic acid on T2-weighted MRCP. Magn Reson Med Sci. 2009;8:143-148.
33. Saito K, Araki Y, Park J, et al. Effect of Gd-EOB-DTPA on T2-weighted and diffusion-weighted images for the diagnosis of hepatocellular carcinoma. J Magn Reson Imaging. 2010;32:229-234.
34. Kim YK, Kwak HS, Kim CS, et al. Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxectic acid. J Magn Reson Imaging. 2009;30:437-443.
35. Tanimoto A, Lee JM, Murakami T, et al. Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol. 2009;19(suppl 5):S975-S989.
36. Doyle DJ, Khalili K, Guindi M, et al. Imaging features of sclerosed heman-gioma. Am J Roentgenol. 2007;189:67-72.
37. Zech CJ, Grazioli L, Breuer J, et al. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol. 2008;43:504-511.
38. Dromain C, de Baere T, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. Am J Roent-genol. 2003;180:121-128. (Pubitemid 36008698)